Inhaled PAMAM-based nano-formulation prolonged lung retention for alleviating pulmonary inflammation of COPD
Chronic obstructive pulmonary disease (COPD) stands as a predominant respiratory disorder intricately linked with respiratory tract microorganisms and their metabolites. Indole acetic acid (IAA), a derivative of tryptophan produced by Lactobacillus salivarius, possesses notable anti-inflammatory pro...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Materials Today Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006425004053 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Chronic obstructive pulmonary disease (COPD) stands as a predominant respiratory disorder intricately linked with respiratory tract microorganisms and their metabolites. Indole acetic acid (IAA), a derivative of tryptophan produced by Lactobacillus salivarius, possesses notable anti-inflammatory properties. However, the short retention time of the drug in lung still remains a vital obstacle leading to a poor bioavailability. In this study, we innovatively engineer a nano-composite by coupling IAA with generation 4 polyamidoamine (G4 PAMAM) dendrimer to form G4-IAA nano-complex through host-guest interaction. G4-IAA shows significantly improved solubility of IAA and thus enhances its bioavailability. This G4-IAA complex facilitates direct aerosol-based pulmonary administration by inhaled strategy, exhibiting enhanced absorption by respiratory epithelial cells and prolonged lung retention. Our experimental findings reveal that inhalation therapy employing the G4-IAA complex mitigates inflammatory stress and augments pulmonary function in COPD murine models. Single-cell sequencing reveals macrophages may contribute to the functional shifts by G4-IAA, promoting an anti-inflammatory phenotype characteristic of M2 polarization. This research introduces a promising therapeutic strategy, offering improved symptomatic relief and reduced risk of acute exacerbations for individuals afflicted with COPD. |
|---|---|
| ISSN: | 2590-0064 |